Clinical Trials
32 trialsStudy of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
University of Colorado, Denver
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Academic and Community Cancer Research United
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
RADIOSARP
Institut Bergonié
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Cedars-Sinai Medical Center
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
University of Washington
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
University of Washington
337
Brown University
CORONADO CLL
University of Utah
Pembrolizumab and Olaparib in Cervical Cancer Patients
Baptist Health South Florida
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Georgetown University
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BAROCCO
Mario Negri Institute for Pharmacological Research
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
University of Washington
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
COMETABreast
Spanish Breast Cancer Research Group
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
M.D. Anderson Cancer Center
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
GOAL
Spanish Lung Cancer Group
A Study of Olaparib and Durvalumab in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Hoosier Cancer Research Network
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Yale University
OLAPCO
Yale University
Polen
MedSIR
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
University of Washington
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
University of Colorado, Denver
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Massachusetts General Hospital
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins